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Abstract: Antipsychotic medications provide the foundation for treatment of acute 
exacerbations as well as relapse prevention in patients with schizophrenia as demonstrated by 
rigorous placebo-controlled trials. However, despite their proven effectiveness, poor adherence 
to prescribed antipsychotic regimens remains the most important driver of suboptimal clinical 
outcomes in this population. This paper reviews the magnitude of the problem of medication 
non-adherence in patients with schizophrenia and the various factors that contribute to non-
adherence, with particular emphasis on factors related to antipsychotic medications. The proﬁ  le 
of the latest atypical antipsychotic, paliperidone extended-release (ER) tablets, is then reviewed 
and the implications of its unique pharmacokinetic proﬁ  le for adherence in this patient popula-
tion are discussed.
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Overview of adherence
Schizophrenia can be a devastating mental illness as it impairs fundamental aspects 
of human emotion and cognition that are essential for successful living in a complex 
social environment. The illness results in distressing consequences for afﬂ  icted patients, 
their family members, and others involved in their care and support, as well as society 
at large in terms of lost productivity and cost of providing treatment, housing, and 
ﬁ  nancial assistance. Over the long term, only a minority of patients are gainfully 
employed or able to live independently. Any new intervention (or improvement in 
current interventions) will have the potential to improve our ability to optimally care 
for those affected.
Currently, antipsychotic medication is the primary treatment modality for the 
management of acute psychosis as well as for relapse prevention in long term 
maintenance treatment (Lehman et al 1998). While other forms of therapies such as 
social skills training, cognitive behavioral therapy, and vocational rehabilitation have 
important roles in the management of patients with schizophrenia, antipsychotics form 
the foundation of treatment and enable symptom attenuation or resolution so that the 
beneﬁ  ts of such therapies can be fully realized. In fact, management of schizophrenia 
cannot be done without appropriate psychotropic treatment both in hospitalized patients 
as well as in outpatients.
The critical importance of optimal adherence to prescribed antipsychotic regimens 
has been repeatedly and convincingly demonstrated in patients with schizophrenia. 
Adherence increases the likelihood of positive outcomes in all aspects of a patient’s 
life including better symptom control (Duncan et al 1998), reduced risk of relapse and 
rehospitalization (Ascher-Svanum et al 2006), and improvement in quality of life and 
social and occupational functioning (Ascher-Svanum et al 2006). Conversely, poor Patient Preference and Adherence 2008:2 234
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adherence results in persistence of symptoms and predisposes 
the patient to relapse which can contribute to a poorer 
long-term prognosis (Wyatt 1991). Lieberman et al (1996) 
conducted a longitudinal study in patients with ﬁ  rst episode 
schizophrenia and found that with each successive relapse, 
response to antipsychotic therapy declined and symptom 
resolution was not as robust. Unfortunately, the current 
state of the effectiveness of our treatment interventions is 
that a signiﬁ  cant minority of patients will relapse despite 
good adherence with prescribed treatment. In one study of 
patients who responded to treatment for their ﬁ  rst psychotic 
episode, up to 82% had at least one relapse within 5 years and 
78% had a second relapse within that time period (Robinson 
et al 1999). As expected, patients who discontinued their 
medication were almost 5 times more likely to relapse then 
patients who continued taking medications. These observa-
tions highlight the importance of clinicians employing all 
strategies available to them to optimize pharmacotherapy and 
enhance adherence with the dual goals of robust symptom 
attenuation and minimization of relapse risk.
Magnitude of poor adherence
The rate of non-adherence in patients with schizophrenia has 
been reported to be as high as 40%–50% (Lacro et al 2002). 
Weiden et al (1991) reported that 74% of schizophrenic 
outpatients who are responsive to medications become 
noncompliant within 2 years post discharge. Even with 
the newer antipsychotics that are believed to be associated 
with fewer side effects and better tolerability, the rates of 
adherence remain poor (Dolder et al 2002).
One major difﬁ  culty in researching and assessing the 
magnitude of non- or poor adherence in schizophrenia is the 
lack of consistent and agreed upon deﬁ  nitions of this phenom-
enon (Velligan et al 2006). For instance, some patients who 
are considered adherent in one study could be categorized as 
non-adherent in another depending on where the distinction is 
made. Adherence cannot be conceptualized as an all-or-none 
phenomenon as only a minority of patients are either “fully 
compliant” or “fully non-compliant” (Velligan et al 2006) – 
most patients lie somewhere in the middle and are partially or 
intermittently compliant. However, it has been demonstrated 
that even minor deviations from prescribed regimens can be 
associated with deleterious outcomes. A 20% reduction in 
medication adherence was found to predict a 3-point increase 
in scores on the positive and negative symptoms scores 
(Docherty et al 2002). Another study reported that a gap in 
treatment of 10 days or less over a 1-year period doubled the 
risk of hospitalization (Weiden et al 2004).
A second limitation in adherence research is that there 
is no reliable methodology for quantifying adherence 
behavior. The most common method used to assess 
adherence is information provided by the patient, which for 
obvious reasons can be signiﬁ  cantly ﬂ  awed (Velligan et al 
2006). Self report requires a direct reliance on the patients’ 
recollection and motivations. Patients may overestimate the 
extent of adherence to please their doctor or avoid confron-
tation. Patients may also unintentionally provide inaccurate 
information due to cognitive impairment resulting in an 
impaired ability to accurately recall their actions (McGrath 
et al 1997). In addition, even among these self report studies, 
methods of collecting data differed signiﬁ  cantly, ranging 
from the use of take home questionnaires and diaries to 
simply having the physician inquire about adherence at 
each interaction. Similarly, prescribers’ assessments of their 
patients’ compliance behavior can be equally ﬂ  awed (Byerly 
et al 2007). They may over- or underestimate a patient’s 
adherence based on the clinical presentation of the patient at 
the time of the interview. Some studies have used the reports 
of signiﬁ  cant others as a means of assessing patient adher-
ence. This, too, may be unreliable for reasons such as the 
degree of involvement of the individual with the patient and 
their particular motivations and understanding of the task.
More direct but still ﬂ  awed “objective” measures that 
have been used in various studies include pill count and 
prescription reﬁ  ll records. Pill counting involves counting 
the number of pills that remain in a prescription bottle 
after an interval of time. Reﬁ  ll records rely on the number 
of prescription reﬁ  lls actually obtained by the patient as a 
proportion of reﬁ  lls that should have been obtained over a 
time interval. Both these methods have the limitation that 
they do not measure whether the pill is actually taken by the 
patient. Electronic pill cap monitoring has been used to count 
the number of times a medication bottle is opened versus how 
many times it should have been opened. Here again, it cannot 
be assessed whether or not the pill was actually ingested.
Urine and blood samples have been used in several 
studies to measure drug levels but this, too, is not completely 
reliable as it can only conﬁ  rm either total absence of drug, 
or if the drug is present in the specimen, that it was taken in 
the recent past (based on the half-life of the drug). Plasma or 
urine level monitoring therefore cannot provide information 
on the patient’s adherence behavior during the entire interval 
between the time points of monitoring.
Despite these methodological limitations it has been 
amply demonstrated in the literature that sub-optimal 
adherence is a major problem in patients with schizophrenia Patient Preference and Adherence 2008:2 235
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and underscores the importance of identifying factors that 
inﬂ  uence adherence and the need to develop interventions 
to improve adherence.
Divers of non-adherence
Several factors that contribute to poor adherence have been 
identiﬁ  ed in compliance research. Some of these are related 
to the illness, such as poor insight and cognitive dysfunction, 
while others are linked to the efﬁ  cacy and tolerability proﬁ  les 
of the medications as well as the route of administration and 
dosing frequency. Other factors include co-morbid substance 
abuse (Dixon 1999) and environmental factors such as 
cultural issues or lack of trust in the treatment team. Multiple 
drivers of good adherence have also been noted. These include 
perceived beneﬁ  t of treatment, fear of hospitalizations, desire 
to avoid unpleasant psychotic symptoms (Weiden et al 1994), 
and desire to please the psychiatrist or other members of the 
clinical team. A good therapeutic alliance will cultivate an 
environment for improved adherence (Bebbington 1995). 
Better efﬁ  cacy and fewer medication side effects will increase 
adherence as will simple medication regimens and a proper 
understanding of illness-associated symptoms and the nature 
of their response to treatment (Degmecic et al 2007).
Lack of insight is one of the most important contributors 
to non-adherence (Buckley et al 2007). Lack of insight 
may range from gross denial of illness and a complete 
rejection of the specific diagnosis to minimization and 
rationalization of symptoms and a lack of appreciation that 
medications are required to treat speciﬁ  c symptoms and to 
reduce the risk of relapse. A signiﬁ  cant number of patients 
with schizophrenia have very poor or complete absence of 
insight into their illness; such patients are more likely to 
demonstrate complete rejection of the need for treatment 
and be chronically non-compliant (Buckley et al 2007). It is 
therefore of utmost importance to assess a patient’s level of 
insight on a continuum and not simply as “good” or “poor.” 
Does the patient recognize the presence of a mental illness, 
the nature of the illness and its associated symptoms, and 
the need for antipsychotic medication for acute as well as 
maintenance treatment? Deﬁ  cits in the ability to recognize 
the presence of a mental illness and the positive therapeutic 
effect of antipsychotics would clearly increase the likelihood 
of poor compliance.
Patients with schizophrenia are known to have impair-
ments in cognition which can interfere with their ability 
to properly comply with prescribed treatment regimens. 
Cognitive deﬁ  cits can contribute to possible confusion and 
failure to execute the act of pill ingestion even when the 
patient is willing and motivated to comply. In one study, 
cognitive function (as compared with age, gender, education 
level, symptom severity, and attitudes toward medications) 
was the strongest patient-related predictor of a patient’s 
ability to manage medications (Jeste et al 2003). Cognitive 
deﬁ  cits can have even greater negative impact on adherence if 
medications have to be taken multiple times during the day or 
multiple medications are prescribed. Greenberg et al (1984) 
demonstrated that patient compliance was as low as 42% for 
medications that required qid dosing and 53% for medications 
that require tid dosing compared with 70% compliance for 
bid and up to 73% compliance for medications that allow for 
a single daily dose. Monotherapy is likely to be less cogni-
tively demanding then polypharmacy, and a reduction in the 
number of different types of medications will decrease the 
likelihood that a patient forgets to take their medications or 
has difﬁ  culty differentiating between tablets. Patients with 
schizophrenia are also less likely to accurately recall whether 
or not they took the medication as prescribed. This further 
compromises the accuracy of monitoring of compliance in 
clinical settings especially if the patient is the only source 
of information regarding compliance behavior.
Psychotic symptoms including delusions, hallucinations 
and thought disorder can interfere with a patient’s ability to 
properly adhere to antipsychotic treatment as well. Kamali 
et al (2006) found that high positive symptoms scores in 
patients at the time of ﬁ  rst episode schizophrenia predicted 
non-compliance at 6-month follow up.
Medication speciﬁ  c characteristics can also affect the 
ability and the desire of the patient to comply with treatment. 
For instance, poor response to antipsychotics has been cited 
as a common reason for stopping medication in schizophrenic 
patients (Liu-Seifert et al 2005). Understandably if the medi-
cation does not appear to be working, adherence is less likely. 
Along similar lines, the usual lag time required to titrate some 
medications up to a therapeutic dose and the delay of days to 
weeks to onset of therapeutic effect in some patients may con-
tribute to non-adherence as patients may lose patience waiting 
for a response and stop the medication. This time lag may also 
make it more difﬁ  cult for the patient to make a connection 
between taking medication and symptom resolution or con-
versely, between medication discontinuation and symptom 
exacerbation (which also does not immediately or invariably 
ensue from medication cessation). Intolerable side effects also 
contribute to poor adherence to treatment. Older generation 
medications such as haloperidol and chlorpromazine were 
associated with high rates of extrapyramidal symptoms 
(EPS) which can be very upsetting and uncomfortable for Patient Preference and Adherence 2008:2 236
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the patient. Akathisia, especially, has been shown to be a 
major reason for medication discontinuation (Van Putten 
1978). Overt movement disorders also make the illness 
more apparent to others further promoting non-adherence 
so as to not attract undue attention. Newer generation 
antipsychotics can lead to metabolic disturbances and weight 
gain which are also difﬁ  cult for the patient to accept and can 
impact negatively on medication adherence. In the Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE) 
(Lieberman et al 2005), the three side effects that resulted 
in increased rate of medication discontinuation were weight 
gain, EPS, and sedation. It is not surprising that some studies 
have reported that older and newer-generation medications 
do not differentially affect adherence (Menzin et al 2003). 
Newer drugs, although less likely to cause EPS, are more 
likely to cause weight gain and be more sedating than the 
older high potency agents. Additionally, the efﬁ  cacy and 
tolerability proﬁ  le of medications is only one of several fac-
tors that affect compliance.
Along with the aforementioned disease-related and 
medication-related drivers of non-adherence, there are a 
number of known potential environmental barriers that a 
patient may need to overcome in obtaining and complying 
with medication. Some of these include the high cost of the 
medications and the difﬁ  culty in getting to the pharmacy. 
Patients may also have to overcome the objection or 
intrusion of family members. Other factors such as the lack 
of a good therapeutic alliance with the treatment team and 
co-morbid substance abuse have also been demonstrated 
to be of signiﬁ  cant importance in inﬂ  uencing compliance 
(Lacro et al 2002).
In summary, several important factors have been identi-
ﬁ  ed that contribute to non-adherence and multiple factors 
will have an additive and potentially compounding effect 
on compliance. The particular combination of factors that 
determine compliance behavior in any given individual is 
quite variable and requires careful clinical assessment as 
a prerequisite for the development of an individualized 
treatment plan. At least some of these factors may be 
amenable to modification from external interventions 
(eg, psycho-education), and some (eg, level of insight) may 
evolve as the patient gains experience through the course of 
the illness. Lastly, as stated earlier, it is important to note that 
deviation from prescribed regimens lies on a continuum from 
full and complete non-adherence to occasional missed doses. 
Patients who completely refuse medications may have very 
different primary drivers for non-adherence (eg, psychotic 
denial of illness) than patients who occasionally miss doses 
(eg, mild cognitive deﬁ  cits in the context of an absent support 
system) (see Table 1).
The preceding review of adherence is not meant to be 
complete and exhaustive and the goal was to provide an 
overview of the phenomenon in which a more detailed 
discussion of medication-related factors can occur.
Implications of pharmacodynamic 
and pharmacokinetic proﬁ  les
of antipsychotics for adherence
As discussed above, it is a well established fact that 
characteristics of antipsychotic medications such as efﬁ  cacy, 
side effects, and dosing frequency affect adherence. Piette 
et al (2007) found that patients with schizophrenia taking 
medications for both schizophrenia and a co-morbid chronic 
medical illness showed differential adherence to medications 
for each individual illness. The authors suggested that factors 
related to the medication themselves and not the limitations 
imposed by schizophrenia were the main determinants 
of differential adherence. However, other factors such as 
differing level of insight into their psychiatric versus medical 
illnesses and perceived beneﬁ  t of different medications may 
also have contributed to the observed differences.
A thorough understanding of how the pharmacody-
namic and pharmacokinetic proﬁ  les of antipsychotics 
translate to the observed clinical proﬁ  les of the drugs is 
of fundamental importance for optimal clinical use of 
these agents. Having this knowledge provides guidance 
for rational dosing of drugs and facilitates the prevention 
(or at least early recognition) of clinical situations in 
which unintended changes in steady-state plasma level 
of the antipsychotic secondary to drug-drug interactions 
potentially alter the efﬁ  cacy or tolerability of the drug. 
Even minor improvements in the tolerability, effectiveness, 
Table 1 Factors positively and negatively affecting adherence
Positive Negative
Perceived beneﬁ  t of treatment Poor insight
Proper psycho-education Cognitive dysfunction; psychotic 
symptoms
Optimal psychopharmacology 
(once a day dosing, few adverse
effects, good efﬁ  cacy)
Side effects (weight gain, sedation, 
orthostasis, akathesia)
Good therapeutic alliance Poor efﬁ  cacy
Fear of hospitalization Substance abuse
Social support Environmental factors (lack of 
trust in physicians, high cost of 
medication, limited social support)Patient Preference and Adherence 2008:2 237
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and ease of use of antipsychotics have the potential to 
improve adherence.
From a pharmacodynamic perspective, medications 
should ideally have much higher afﬁ  nity for those receptors 
(eg, D2, 5HT2A) that are implicated in efﬁ  cacy compared 
to those that mediate side effects, such as H1 (sedation and 
weight gain) and α-1 (orthostasis). Thus, at the desired 
therapeutic dose such a drug would occupy the speciﬁ  c 
“efﬁ  cacy” target receptors and tend to minimally involve other 
receptors, translating to an improved efﬁ  cacy/tolerability 
proﬁ  le and potentially better adherence. Unfortunately, an 
agent with such an ideal receptor binding proﬁ  le currently 
does not exist. In fact, for some agents (eg, quetiapine, 
clozapine) the affinity for the H1 and α-1 receptors is 
substantially higher than for the D2 receptor and dose titration 
is required to minimize the risk of sedation and orthostasis, 
respectively – this need for dose titration for some agents 
further delays the time to onset of therapeutic effect. One 
strategy that has been developed to overcome this limitation 
of mandatory titration for some agents is to deliver a larger 
dose of the drug over an extended period of time by utilizing 
extended-release formulations. By avoiding the high peak 
plasma levels associated with immediate-release formula-
tions it is possible to initiate treatment at a larger dose which 
is close to or at the therapeutic dose for that drug. This either 
eliminates the titration phase or substantially reduces its 
duration. Extended-release formulations also enable drugs 
with short half-lives to be administered once daily, which 
simpliﬁ  es the dosing regimen and has a potential positive 
impact on patient adherence. Quetiapine SR (slow release) 
and paliperidone ER (extended release) are examples of 
extended-release formulations.
In general, antipsychotic drugs are taken orally and after 
being absorbed in the gut must pass through the liver before 
reaching the systemic circulation and ultimately their target 
site of action in the brain. The drug undergoes ﬁ  rst-pass 
metabolism in the liver which results in inactivation of a 
fraction of the drug. About 5%–10% of Caucasians are 
poor metabolizers” and have limited activity of the P-450 
2D6 isoenzyme pathway. Such patients may end up with 
unusually high plasma levels on the usual therapeutic dose 
of a drug (eg, risperidone) that is primarily metabolized by 
this pathway, resulting in higher rates of adverse events and 
poor tolerability. This was conﬁ  rmed in the study of De Leon 
et al (2005) in which poor metabolizers had a 2-fold higher 
odds ratio of discontinuing risperidone due to adverse drug 
reactions compared to normal (extensive) metabolizers. 
Although a genetic test is now available to identify poor 
metabolizers, it is quite expensive and not yet in routine 
clinical use.
Since most antipsychotics are metabolized in the liver 
there is also the potential risk for drug-drug interactions 
mediated by induction or inhibition of the P-450 isoenzyme 
system. Polypharmacy increases the likelihood of drugs 
interacting at the level of the liver and affecting the blood 
levels of either the drug itself or other medications that 
are co-administered. Antipsychotics do not signiﬁ  cantly 
induce or inhibit the P-450 isoenzymes but may be subject 
to drug-drug interactions if they are co-administered with 
another drug known to affect the pathway that is relevant 
in their metabolism. Depending on whether the relevant 
P-450 enzymes are induced or inhibited, such drug-drug 
interactions may result in levels of the antipsychotic that 
are either sub-therapeutic and have a less then optimal 
therapeutic effect, or are too high and cause unwanted side 
effects, respectively. Examples of potent inducers of the 
P-450 3A4 enzyme system include carbamazepine and 
phenytoin, while common inhibitors include the macrolide 
antibiotics, some antifungals, and most protease inhibitors. 
Fluoxetine and paroxetine are potent inhibitors of the 2D6 
isoenzyme. Depending on the primary metabolic pathway 
of the antipsychotic, a dose adjustment may be necessary 
if a P-450 inducer or inhibitor is co-administered with the 
antipsychotic. In a study by Deleon et al (2005), concomitant 
use of 2D6 inhibitors (ﬂ  uoxetine or paroxetine) and risperi-
done was found to increase the discontinuation rate due to 
adverse drug reactions of risperidone from 30% to 53%.
We will now proceed with a review of the proﬁ  le of 
paliperidone ER, the most recent atypical antipsychotic to 
receive FDA approval, and discuss possible implications 
of its unique characteristics for improving adherence in 
patients with schizophrenia. The review of paliperidone 
ER is relevant in this context because it is the ﬁ  rst atypical 
antipsychotic that is not metabolized by the liver and has 
a unique delivery system that minimizes peak to trough 
plasma level ﬂ  uctuations. It is important to highlight that 
the following discussion of the potential impact of its unique 
pharmacokinetic proﬁ  le on adherence, although logical and 
rational, is speculative and has yet to be demonstrated. We 
hope to raise questions for further investigation pertaining 
to antipsychotic adherence.
Paliperidone ER
In December 2006, paliperidone ER was approved by the FDA 
for the treatment of schizophrenia in the United States and has 
since been approved in several other countries. Paliperidone Patient Preference and Adherence 2008:2 238
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ER was formulated to combine the active metabolite of 
risperidone (9-OH risperidone) with an osmotic controlled-
release oral delivery system (OROS) that minimizes peak to 
trough ﬂ  uctuations. Paliperidone’s mechanism of action is 
believed to result from its high antagonist activity at the D2 and 
5-HT2A receptors. It also has additional antagonistic afﬁ  nity 
for the histaminic H1 and adrenergic α-1 and α-2 receptors. 
It has no afﬁ  nity for the muscarinic cholinergic receptors.
The osmotic controlled-release formulation enables 
slow release of paliperidone over a 24-hour period. After 
a single oral dose, the plasma concentration gradually rises 
to reach a peak plasma concentration at about 24 hours. 
Plasma level ﬂ  uctuation is reduced with a peak to trough 
ﬂ  uctuation of only 38% for a 12 mg dose of paliperidone 
ER (which is the maximum approved dose), compared with 
125% for a 4 mg dose of risperidone immediate-release 
formulation (Paliperidone Product Monograph 2007) 
(Figure 1). A smoother proﬁ  le of antipsychotic plasma level 
with limited peak to trough ﬂ  uctuation has implications 
for the overall efficacy/tolerability profile of the drug. 
At any given therapeutic dose (or plasma level), lower 
peaks can be predicted to be associated with a lower risk 
of at least those side effects that are dose-related such as 
sedation, orthostasis, and EPS. The limited plasma level 
ﬂ  uctuation with paliperidone ER is also reﬂ  ected in lesser 
ﬂ  uctuation in D2 receptor occupancy in the brain compared 
with the immediate-release formulation. A dose of 6 mg of 
paliperidone ER provides a mean D2 receptor occupancy of 
64% at 22 hours post dose (Karlsson et al 2006), which is 
in the desirable range (60%–80%) for antipsychotic effect 
without exceeding the 80% D2 receptor occupancy threshold 
associated with adverse motor side effects. This dose can 
be administered from Day 1 as the risks of orthostatic 
hypotension and other unwanted side effects are substantially 
reduced by the slow release of the medication. Initiating 
treatment at a therapeutic dose has the added beneﬁ  t of 
decreasing the lag time between medication initiation and 
onset of therapeutic effect. In the clinical trials conducted for 
regulatory approval, onset of signiﬁ  cant therapeutic effect 
was evident at the ﬁ  rst post-baseline assessment point of the 
studies (Day 4 of treatment). The half-life of paliperidone 
is approximately 23 hours which allows for once-a-day 
dosing and results in steady state plasma levels in 4–5 days. 
The relatively long half-life also limits possible detrimental 
consequences of occasional missed doses.
Another distinguishing feature of paliperidone ER, 
other than its delivery system, is that it is the ﬁ  rst and only 
antipsychotic that is not metabolized by the P-450 isoenzyme 
system, and is only minimally metabolized by other pathways 
in the liver; approximately 60% is eliminated unchanged 
in the urine. Thus, paliperidone would not be expected 
to be subject to drug-drug interactions mediated through 
the P-450 system and its dosing would not be expected to 
differ between slow and rapid metabolizers. The potential 
for important drug-drug interactions was highlighted in a 
recently conducted naturalistic analysis across 10 European 
countries which found that up to 29% of outpatients with 
schizophrenia were receiving concomitant anticholinergic 
medications, up to 23% were on antidepressants, up to 
37% on anxiolytics, and up to 19% on mood stabilizers 
(Haro et al 2006). Such high rates of concomitant therapy 
dramatically increase the likelihood of clinically signiﬁ  cant 
pharmacokinetic drug-drug interactions with unintended 
consequences for efficacy or tolerability. In addition, 
individuals with schizophrenia are known to be at increased 
risk for infection with HIV, hepatitis C, or both (Cournos 
et al 2005), as well alcohol abuse (Dixon 1999). These 
co-morbidities can compromise hepatic function directly 
thereby affecting metabolism of drugs metabolized in the 
liver placing patients with schizophrenia at increased risk 
for adverse drug reactions. Additionally, some of the drugs 
used to treat these disorders (eg, protease inhibitors) may be 
inhibitors of some CYP-450 pathways, further complicating 
treatment by creating potential for drug-drug interactions. 
The limited hepatic metabolism of paliperidone ER renders 
it essentially free of the potential for adverse drug-drug 
interactions; additionally, no dose adjustments are required 
for patients with mild to moderate hepatic impairment 
or for those who are slow metabolizers (Paliperidone 
Prescription Information 2008). This potentially enhances 
Paliperidone ER (n = 37) Oral risperidone (n = 37)
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the predictability of clinician dosing resulting in improved 
efﬁ  cacy/tolerability and therefore improved compliance.
Three randomized, double-blind, placebo-controlled, 
parallel-group, 6-week trials investigated the efﬁ  cacy, safety, 
and tolerability of paliperidone ER at doses of 3–15 mg per day 
(Davidson et al 2007; Kane et al 2007; Marder et al 2007). 
All doses signiﬁ  cant reduced schizophrenia symptomatology, 
with an onset of effect as early as day 4. The FDA-approved 
dose range is 3–12 mg/day with a recommended starting dose 
of 6 mg/day. EPS and weight gain were comparable to placebo 
in the 3- and 6-mg/day groups but higher than placebo in 
the 9- and 12-mg/day dose groups. Importantly, the slightly 
higher rates of EPS in the 9- and 12-mg/day dose groups 
were not associated with a higher discontinuation rate due 
to adverse events compared to the placebo group. Prolactin 
elevation was comparable to that reported in studies with 
risperidone (Paliperidone Product Monograph 2007).
Conclusion
Adherence to antipsychotic medication is the single most 
important determinant of long-term clinical outcome in 
patients with schizophrenia. Those individuals who are 
willing and able to fully comply with their treatment regimen 
will likely maximize their chance of recovery and reduce their 
risk of relapse over the course of the illness.
A clear understanding by the treatment team of the patient’s 
perspective on their illness and the beneﬁ  ts and risks of 
antipsychotic treatment (both real and imagined) is the starting 
point for the formulation of an intervention plan to improve 
adherence. In any given patient, it is important for clinicians 
to determine the speciﬁ  c reasons for poor adherence and then 
tailor treatment and other interventions accordingly. The 
importance of targeted education about mental illness and the 
medications used to treat them, with particular focus on the 
importance of medication adherence and problems that may 
arise if medications are discontinued, is self evident (Degmecic 
et al 2007). Providing instructions, or teaching skills that may 
make medication adherence easier and less demanding is also 
helpful (Lacro 2006). Improved communication between 
patients and providers, getting family members involved, 
and behaviorally focused interventions such as reinforcing 
speciﬁ  c medication-taking patterns have all been shown to 
help improve patient adherence. Interventions that include all 
or most of the aforementioned strategies are typically the most 
successful (Dolder et al 2003). Intra-muscular injections of 
depot medications are also available for those patients who are 
unable or unwilling to comply with oral medications or have 
repeatedly failed to adhere to daily medication regimens.
For the medications themselves, simplifying medication 
regimens as much as possible may help patients remain 
adherent. This makes the task of medication taking less 
daunting and cognitively taxing. Whenever possible, 
medications should be administered once daily. It is imperative 
that clinicians be aware of the pharmacodynamic and phar-
macokinetic proﬁ  les of the agents they use so as to optimize 
dosing strategies and recognize situations in which potential 
drug-drug interactions may occur. Avoiding unnecessary 
polypharmacy and limiting the number of different medica-
tions to the minimum required for control of symptoms will 
not only make monitoring of clinical response and side effects 
in patients easier but also help reduce the potential for unin-
tended adverse drug interactions and improve adherence.
The unique pharmacokinetic property of paliperidone 
ER raises several important questions related to adherence. 
Does the limited ﬂ  uctuation in plasma level of the medication 
improve tolerability and will that translate to improvement in 
adherence in patients with schizophrenia? Does avoidance of 
the P-450 system reduce the potential for unwanted drug-drug 
interactions in real world settings? Is the dosing of paliperi-
done ER similar for slow versus fast metabolizers and those 
with hepatic impairment, as would be predicted by its limited 
hepatic metabolism? Does the limited hepatic metabolism 
reduce inter-patient variability in plasma level at any given 
dose secondary to limited ﬁ  rst-pass metabolism? If so, does 
this improve the accuracy of clinician dosing which would in 
turn improve efﬁ  cacy and tolerability and possibly adherence? 
Future research needs to address these important questions.
When choosing among available antipsychotics the 
important question is not whether one drug is better than 
the other but, rather, the efﬁ  cacy attributes and side effect 
limitations of each drug, and how to dose appropriately each 
agent based on the diagnosis of the patient, stage of illness, 
and other factors such as concomitant therapy with potential 
for drug-drug interactions. This knowledge will surely enable 
us to make optimal risk beneﬁ  t judgements when we choose 
among various available options for individual patients.
Disclosures
Dr Sharif is on the speakers’ bureau for Janssen, Bristol 
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